Emergent BioSolutions shares soared 18% in after-hours trading after a surprise Q3 profit and raised 2025 outlook. Revenue grew double digits on strong Narcan and smallpox vaccine sales, with improved margins and lower costs. Retail sentiment on Stocktwits turned ultra-bullish as traders bet on more upside.